You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
The wastewater analytics firm will work with the two government agencies to analyze samples from treatment plants across the US for SARS-CoV-2 viral elements.
The investment bank sees the potential for strong revenue growth over time as Oncocyte expands its product portfolio and launches new tests.
Last week, GenomeWeb's readers were most interested in Somalogic's news of having closed a $121 million Series A funding round.
The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The company sells miniaturized mass spectrometers and microfluidic separations systems for use in applied markets and life science and drug research.
The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.
The RT-PCR-based test was first authorized earlier this year for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.
The test uses a targeted methylation sequencing panel to detect more than 50 cancer types across all stages and pinpoint a cancer's tissue of origin.
Twenty-nine new studies highlight how time in space affects the human body, including effects on telomeres, mitochondria, and more.
A team led by researchers at University College London studied mutations in almost 47,000 viral genomes collected from patients worldwide.
The company said it will use proceeds from the round, which was led by Casdin Capital, to expand and commercialize its SomaScan platform and SomaSignal tests.
An integrated proteogenomic analysis led to previously unappreciated treatment targets or prognostic markers in craniopharyngioma, high-grade glioma, and other tumor types.
News items for the week of Nov. 23, 2020.
The FDA also reissued Emergency Use Authorizations for SARS-CoV-2 tests from Roche and Express Gene to reflect their permitted use with additional sample types.
The xT platform integrates structured clinical patient data with results from a 648-gene DNA panel and whole-transcriptome RNA sequencing.
The alliance of hospitals, research groups, and academic institutes is tasked with implementing clinical genomics programs in Australia's state of Victoria.
Researchers retraced clusters of related cases with epidemiology and deep sequencing of SARS-CoV-2 samples collected in Austria in the spring.
The investment bank said it expects demand for Fulgent's COVID-19 testing to decline over the next two years.
Cepheid said that the 4-in-1 test runs on any of almost 30,000 GeneXpert Systems, which provide results in approximately 36 minutes.
Under the terms of the agreement, OpGen would sell $10 million in stock and warrants to a US-based healthcare-focused institutional investor.
For the three months ended Oct. 31, revenues rose to $1.48 billion from $1.37 billion in Q4 2019, beating the average Wall Street estimate of $1.4 billion.
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.
The Warsaw, Poland-based firm has secured nearly €20 million ($23.7 million) this year to advance its PCR One point-of-care molecular diagnostic system.
Exome array-wide association and rare variant-focused genome-wide association meta-analyses led to 87 rare variants with ties to one or more blood pressure traits.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.